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Recepteur d’Origine Nantais (RON) is a distinct receptor tyrosine kinase in the c-met proto-oncogene family. We examined the
mutational and expression patterns of RON in eight human uroepithelial cell lines. Biological effects of RON overexpression on
cancer cells were investigated in vitro, and the prognostic significance of RON and/or c-met protein (MET) expression was analysed in
a bladder cancer cohort (n¼183). There was no evidence of mutation in the kinase domain of RON. Overexpression of RON using
an inducible Tet-off system induced increased cell proliferation, motility, and antiapoptosis. Immunohistochemical analysis showed
that RON was overexpressed in 60 cases (32.8%) of primary tumours, with 14 (23.3%) showing a high level of expression. Recepteur
d’Origine Nantais expression was positively associated with histological grading, larger size, nonpapillary contour, and tumour stage
(all Po0.01). In addition, MET was overexpressed in 82 cases (44.8%). Co-expressed RON and MET was significantly associated with
decreased overall survival (P¼0.005) or metastasis-free survival (P¼0.01) in 35 cases (19.1%). Recepteur d’Origine Nantais-
associated signalling may play an important role in the progression of human bladder cancer. Evaluation of RON and MET expression
status may identify a subset of bladder-cancer patients who require more intensive treatment.
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Protein tyrosine kinases (PTKs) are a major class of proto-
oncogenes and play a crucial role in many cell regulatory
processes, such as proliferation, migration, adhesion, and,
potentially, cellular transformation. Currently, most of the
established proto-oncogenes in solid tumours are PTKs. The
type-1 ErbB family receptors – epidermal growth factor (EGF)
receptor and ErbB2 (c-erbB-2, HER-2/neu) – are well-known
examples. Dimerisation by binding two monomers is the
regulatory mechanism for the activation of tyrosine kinase
receptors (Heldin, 1995). In some cases, formation of hetero-
dimeric complexes allows interaction and cross-talk between
different receptors of the same subfamily, and the ErbB receptor
family is the best example of homo- and hetero-dimerisation in
vivo (Wada et al, 1990; Sliwkowski et al, 1994; Pinkas-Kramarski
et al, 1996; Chow et al, 2001). Therefore, determining the clinical
significance of the co-expression pattern of PTKs can provide
important molecular targets for cancer therapy.
Recepteur d’Origine Nantais (RON), also known as stem-cell-
derived tyrosine kinase in mice, is a distinct receptor tyrosine
kinase in the MET proto-oncogene family (Ronsin et al, 1993). The
ligand for RON was identified as macrophage-stimulating protein
(MSP) (Wang et al, 1994), expressed by renal tubular cells
(Rampino et al, 2002). Recepteur d’Origine Nantais induces cell
transformation and epithelial tumorigenesis (Collesi et al, 1996;
Santoro et al, 1996; Peace et al, 2001; Chen et al, 2002). In primary
human cancer, highly expressed RON was observed in 47% (35 of
74 cases) of breast cancers and 59.2% (29 of 49 cases) of colorectal
cancers (Maggiora et al, 1998; Zhou et al, 2003).
In our prior profiling experiment (Cheng et al, 2002), RON was
one of the receptor-type PTKs expressed in bladder cancer cells.
Interestingly, this receptor protein and its cognate ligand MSP are
all located within chromosome 3p21.3, a region frequently
amplified in human bladder cancer (Koo et al, 1999). As crosstalk
between RON and MET was observed in epithelial cancer (Chen
et al, 1997; Maggiora et al, 2003), we investigated the clinical
significance of RON and MET overexpression in human bladder
cancer.
MATERIALS AND METHODS
Immunoprecipitation
Urine samples (n¼32) were concentrated using a centrifugal filter
device with a molecular weight cutoff of 50kDa (UltraFree-4;
Millipore, Bedford, MA, USA) as described previously (Yan et al,
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s2001). Protein concentrations of the concentrated urine samples
were determined using the Micro BCA method (Pierce Chemical,
Rockford, IL, USA). Equal amounts of proteins (20mg) were loaded
onto 4–15% gradient gels and separated using sodium dodecyl
sulphate (SDS)–polyacrylamide gel electrophoresis under non-
reducing conditions. Resolved proteins were electrophoretically
transferred to TransBlot nitrocellulose membranes (Bio-Rad,
Richmond, CA, USA). The membranes were blocked with 5%
low-fat dry milk in TBS-T (10mM Tris, pH 7.2, 50mM NaCl, 0.5%
Tween 20) for 1h at room temperature, followed by incubation
with primary antibody (1:100 dilution) against human MSPa
(R&D Systems, Minneapolis, MN, USA) at 41C for 18h. Blots were
washed eight times with TBS-T (5min per wash) and incubated
with a 1:5000 dilution of horseradish peroxidase-conjugated
secondary antibody (Vector Laboratories, Inc., Burlingame, CA,
USA) diluted in TBS-T containing 3% bovine serum albumin for
1h at room temperature. Labelled proteins were visualised with
enhanced chemiluminescence (Amersham Biosciences Corp.,
Piscataway, NJ, USA). Cell lysates from HepG2 and UB37 were
used as positive controls. Informed consent was obtained from all
patients before their urine was taken for analysis.
Cell lines and culture
Four human bladder cancer cell lines (RT4, TSGH-8301, TCC-SUP,
and T24) were propagated for use, as described previously (Cheng
et al, 2002). The locally established cell lines UB09, UB37, UB40,
and UB47 were derived from transitional-cell bladder cancer of
grade II pT2, grade III pT3, grade III pT1, and grade III pT3,
respectively. They were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco BRL, Grand Island, NY, USA) supple-
mented with 10% foetal calf serum (Gibco BRL), L-glutamine
(2mmoll
 1), sodium pyruvate (110mgl
 1), penicillin
(100Uml
 1), and streptomycin (50gml
 1)a t3 7 1C in a 5%-CO2-
humidified atmosphere. Primary culture of uroepithelium was
obtained from a patient with non-neoplastic urinary disease, and
maintained in keratinocyte-SFM (Gibco BRL), supplemented with
bovine pituitary extract (20–30mgml
 1), 10% foetal calf serum
(Gibco BRL), and EGF (0.1–0.2ngml
 1) as described previously
(Adam et al, 2003).
Chemicals and plasmids
Wortmannin was obtained from Sigma (Sigma-Aldrich, St Louis,
MO, USA). Plasmid pLP-TRE2-RON was constructed in our
laboratory, and co-transfected with pTet-Lac-Hygo in the sub-
sequent experiments as described (Chow et al, 2003). In this study,
the Tet-off system using doxycycline was used to regulate
exogenous RON expression.
Preparation of total RNA and real-time polymerase chain
reaction (RT–PCR) analysis
Total RNA was extracted using Trizol reagent (Invitrogen Corp.,
Carlsbad, CA, USA). First-strand cDNA was synthesised in a total
volume of 20ml using an M-MLV Reverse Transcriptase kit
(Invitrogen). The Roche LightCycler Real-time PCR system (Roche
Diagnostics Corporation, Roche Applied Science, Indianapolis, IN,
USA) was used to quantify the expression of target genes with
SYBR Green I labelling. Polymerase chain reactions were
performed in a total volume of 10ml containing 3ml cDNA
(1:100 dilution), 2.5mM MgCl2,1 0 p M forward and reverse
primers, 1ml SYBR Green I, and 4.8ml PCR-grade H2O. The
reaction was performed for 7min, to denature DNA and activate
the Hot-Start polymerase, followed by 50 PCR cycles denatured
at 951C for 10s, annealed at 601C for 5s, and elongated at 721C
for 12s in glass capillaries. The primers used were: RON receptor
forward 50-AGCCCACGCTCAGTGTCTAT-30, RON receptor re-
verse 50-GGGCACTAGGATCATCTGTCA-30; PPIA forward 50-
GTTTGCAGACAAGGTCCCA-30, and PPIA reverse 50-ACCCGTAT
GCTTTAGGATG-30.
Western blot analysis
In all, 50mg of total protein was denatured in SDS lysis buffer
(Tris-HCl (50mM), pH 6.8, SDS (2%), glycerol (10%), and
dithiothreitol (100mM)) and then loaded into duplicated 12%
SDS–polyacrylamide gels. After electrophoresis, one of the gels
was stained with 0.5% colorimetric Coomassie brilliant blue
(Sigma) as a quantitative control. The other gel was transferred
to a polyvinylidene difluoride membrane (Stratagene, La Jolla, CA,
USA) and blocked with 5% skimmed milk in PBST (sodium
chloride (100mM), disodium hydrogen phosphate (80mM), sodium
dihydrogen phosphate (20mM), Tween 20 (0.2%), pH 7.5) solution
at 41C overnight. After being washed with PBST and phosphate-
buffered saline, the membrane was hybridised with the monoclonal
antibodies for MET, RON, or b-actin (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA) at 371C for 1h. The membrane was then
incubated with anti-rabbit or anti-mouse IgG conjugated with
horseradish peroxidase at 251C for 1h. After being thoroughly
washed, the membrane was exposed to radiographic film following
a reaction with enhanced chemiluminescence detection reagents
(Amersham). Human b-actin was used as an internal control.
Single-strand conformation polymorphism analysis and
mutation analysis of the RON gene
Each exon of the kinase domain, plus a region containing the
proteolytic cleavage site in exon 1, was examined for mutation
using a specific PCR primer pair as described previously (Angeloni
et al, 2000). First-strand cDNAs from primary uroepithelium,
UB40, and UB47 cells were prepared using reverse transcription of
1mg of RNA, according to the instructions for the SuperScript
preamplification system (Gibco BRL). The primers used for
amplification of RON for PCR were chosen from a prior report
(Collesi et al, 1996). To check for potential mutations of RON,
genomic DNA was also amplified using two primers flanking this
region: sense oligomer corresponding to nucleotides 2619–2641
(50-ATCCACCCAGTGCCAACCTAGTT-30) and antisense oligomer
corresponding to nucleotides 2873–2895 (50-GGCCAGATGGGGT
CCCACA GAG-30) (Collesi et al, 1996). Each sequence was
confirmed with two independent PCR reactions.
Cell viability staining
The cells were re-suspended in DMEM medium. Equal volumes of
cell suspension and ethidium-bromide/acridine-orange solution
were mixed and placed underneath the cover slides. The cells were
observed under a microscope. The live cells labelled with acridine
orange are green, and the dead cells labelled with ethidium
bromide are orange. The cells were counted and their viability was
calculated.
Wound-healing assay
The UB09 cells (3 10
6) were seeded on a 30-mm dish overnight
after transfection. A mid-line wound was made on the monolayer
cells, and the healing process was recorded every 20min until the
wound was completely healed (Ho et al, 2005). The Image-Pro plus
computer program (Media Cybernetics, San Diego, CA, USA) was
used to calculate the distance between the wounded edges.
Clinicopathologic characteristics
For this study, archival blocks were collected from 183 patients
(117 men and 66 women; age range: 23–93 years old; mean age:
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s64.2710. 4 years) with primary TCC of the urinary bladder treated
at our hospital between July 1, 1988, and July 31, 1994. Patients
with primary carcinoma in situ were excluded from this study. The
study protocol was approved by the Human Investigations
Committee in our hospital. All cases were reviewed for histological
grade according to the World Health Organization classification
(Eble et al, 2004). Clinical staging was determined according to the
Tumor-Node-Metastasis System of the Union Internationale
Contre le Cancer (Sobin and Wittekind, 2002) using a survey of
the clinical details, image studies, and pathologic data. But no
definite tumour staging could be determined at diagnosis in 10
patients (5.5%). This cohort was different from our prior study on
MET (Cheng et al, 2002).
The treatment and follow-up of patients were conducted
according to the standard strategy previously described in detail
(Cheng et al, 2002). Briefly, all patients with superficial bladder
cancer (n¼93) received transurethral resection and postoperative
intravesical chemotherapeutic agent instillation with either thio-
tepa (30mg in 30ml of normal saline for 70 patients) or epirubicin
(40mg in 40ml of normal saline for 34 patients) weekly for 8
consecutive weeks. Those patients who received intravesical
bacillus Calmette-Guerin therapy or neoadjuvant chemotherapy
were excluded from this study to preclude any potential bias in
prognostic correlation (e.g. recurrence rate or tumour progres-
sion). The patients were followed up every 3 months for the first 2
years, every 6 months for another 2 years, and yearly thereafter.
Recurrent tumours were confirmed by biopsy, and the patient
was given a transurethral operation. This was followed by another
8-week course of intravesical chemotherapeutic instillation
therapy or by a radical or partial cystectomy if there was disease
progression. Disease progression at recurrence was defined as
being at a higher stage than the previous result. In all, 77 patients
with muscle-invasive tumours were given a radical cystectomy, and
nine patients were given a partial cystectomy. The four patients
with distant metastasis at diagnosis received a transurethral
resection only. A total of 75 patients received systemic chemo-
therapy with methotrexate (MTX), cisplatin, doxorubicin, and
vinblastine. Survival status was determined by checking outpatient
clinic records, interviewing patients’ families, or both. Clinical
follow-up ranged from 24 to 95 months (median: 54 months).
Immunohistochemistry (IHC) of RON and MET expression
Immunostaining procedures were described previously (Cheng
et al, 2002). Briefly, tissue sections were incubated at room
temperature for 2h with monoclonal anti-MET and anti-RON
antibodies (Santa Cruz Biotechnology) raised against human MET
or RON protein, respectively. The optimal dilution (1:100) was
determined using human kidney tissue as a positive control
(Rampino et al, 2002). The StrAviGen Super Sensitive MultiLink
kit (BioGenex Laboratories, Inc., San Ramon, CA, USA) was used
to detect the resulting immune complex. Peroxidase activity was
visualised using an aminoethyl carbazole substrate kit (Zymed
Laboratories, Inc., San Francisco, CA, USA). Finally, sections were
counterstained with haematoxylin. For the negative control, non-
immune mouse immunoglobulin was substituted for the primary
antibody in the incubation.
When they evaluated the staining results, the reviewers (N-HC
and C-LH) were blinded to the clinical outcomes. Since there was
no apparent difference in staining intensity, we used a three-
category scoring system for RON and MET based on the
proportion of tumour cells stained, as described previously (Chow
et al, 2001; Cheng et al, 2002). ‘High level of expression’ indicates
that more than 50% of the tumour cells exhibited immunostaining;
‘low level of expression’, between 10% and 50% reactivity; and
‘negative’, less than 10% or zero staining for RON protein.
Statistics
Correlations between RON or MET expression and clinicopatho-
logic indicators of bladder cancer, and the biological effects of
RON expression on cancer cells were examined, where suitable,
using analysis of variance, Fisher’s exact test, or w
2 test. The
relationship between IHC expression pattern or biological
indicators and clinical outcome was analysed using a multiple
logistic regression model. Overall survival was calculated using
Kaplan–Meier analysis, and the Cochran–Mantel–Haenszel test
(log-rank test) was used to assess the significance of RON and MET
expression in relation to tumour recurrence or patient survival.
The relative risk (RR) in relation to patient prognosis was assessed
using a Cox proportional hazards model after adjustment for
clinicopathologic parameters. Only those variables with a P-value
o0.05 were considered significant.
RESULTS
Measurement of MSP in human urine
To examine the involvement of MSP/RON signalling in bladder
carcinogenesis, we analysed the appearance of urinary MSP in a
total of 17 cases of urothelial carcinomas (two grade 1, nine grade
2, and six grade 3) and 15 cases of non-neoplastic inflammatory
urinary tract diseases. Immunoprecipitation showed that 10 of 17
with cancer and one with an inflammatory urinary tract disease
had detectable urinary MSP (P¼0.04). Representative results of
cancer (n¼9) and xanthogranulomatous pyelonephritis (n¼1)
cases are shown in Figure 1. The appearance of urinary MSP was
basically independent of the RON expression status in primary
tumours (data not shown). These results imply that the activation
of MSP/RON may be involved in the development of human
bladder cancer.
Expression of RON and MET receptors in uroepithelial cell
lines
The expression of RON was examined at the mRNA level using
RT–PCR in a primary culture of uroepithelium and eight cancer
cell lines (Figure 2). TCCSUP had the highest level of RON
expression in this panel, while the other seven cancer cell lines had
variable level of RON expression, with RT4 being the lowest one.
Unexpectedly, primary culture of uroepithelium was found to have
high RON expression.
Then, expression of RON was assessed at protein level using
Western blot (Figure 3). Primary uroepithelial cells and seven of
HepG2 E6 Urine 
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Figure 1 Immunoprecipitation of MSP in human urine. All nine patients with transitional-cell bladder cancer had detectable MSP in their urine, but MSP
was not measurable in the urine of patients with xanthogranulomatous pyelonephritis (case 772). The column of DMEM was taken from medium used for
culturing of HepG2 and UB37 cells.
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sthe eight cancer cell lines expressed both the mature form of
p150RON and precursor p180RON, except that RT cells had very
low level of RON expression. All of the UB series cancer cell lines
expressed RON protein. The expression pattern in Western blot
basically corresponds to that of RT–PCR. These results suggest
that RON-associated signalling events play an important role in the
progression of bladder cancer.
However, we have no complete rationale to explain for high level
of RON expression in primary culture of uroepithelial cells. A prior
study using SV40 large-T antigen immortalised UROtsa cells
showed that cells grown in serum-free growth conditions have a
phenotype most like the intermediate layers of the urothelium
(Rossi et al, 2001). Therefore, it is plausible to speculate that
primary culture grown in serum-enriched media may exhibit a
distinctly different phenotype.
To determine whether constitutive activation of RON is caused
by mutations in the kinase domain of RON, genomic DNA was
submitted for single-strand conformational polymorphism screen-
ing using a panel of intron-based primers covering exon 1 and
exons 14–20 of the RON gene. The amplified DNA fragments were
also sequenced. No mutations were found in the kinase domain of
the RON gene in any of the cell lines tested (Chow et al, 2003).
All of the uroepithelial cells expressed mature p140
MET and
precursor p170
MET, except that a relatively lower level of p170
MET
was observed in TCCSUP cells (Figure 2). Altogether, co-
expression of RON and MET was a universal event in uroepithelial
cells, highly suggestive of the potential clinical significance of
crosstalk between RON and MET.
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Figure 2 Reverse transcriptase–polymerase chain reaction measure-
ment of RON expression at mRNA level. TCCSUP had the highest level of
RON expression in this panel of uroepithelial cell culture, while the other
seven cancer cell lines had variable levels of RON expression, with RT4
being the lowest one. Primary culture of uroepithelium was found to have
unusually high RON expression. All reactions were performed in triplicate.
Data are expressed as relative amounts of RON mRNA levels in relation to
PPIA.
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Figure 3 Expression of RON and MET receptor proteins in uroepithelial
cells. Primary culture of uroepithelial cells and seven cancer cell lines
expressed a mature form of p150
RON and a precursor p180
RON, except
that RT cells had very low level of RON expression. All the uroepithelial
cells expressed mature p140
MET and precursor p170
MET, except that
TCCSUP cells expressed a relatively lower level of precursor p170
MET.
These results indicate that co-expression of RON and MET is a universal
event in uroepithelial cells.
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Figure 4 Growth curve of UB09 cells after transfection of RON. The
cells (1 10
4 per well for six wells) were cultured in 10% serum-containing
medium with or without doxycycline (1mgml
 1). The cell number was
calculated from 3 to 9 days using a cell counter. Those cells expressing
higher RON had a significantly faster growth rate, as indicated by asterisks
(P¼0.0028, t-test).
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Figure 5 Time-lapse recording of cell migration in UB09 cells after
transfection of RON. The cells (5 10
5) were plated on a 1-cm cover slide
and grown for 1 day, during which the cells formed a monolayer. Cells were
then wounded with a yellow tip. The healing of the wounds was recorded
every 20min for a total of 20h. (A) Distance of wounding of UB09/RON
and UB09 cells, respectively. (B) Quantitative data of migration distance for
UB09/RON and UB09 cells, respectively. Overexpression of RON
increased the migration distance, symbolic for cell motility, of cancer cells
(P¼0.04, t-test).
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Figure 6 Antiapoptosis by acridine orange staining of the UB09/RON cells after MTX treatment. (A) UB09 cells were electroporated with 40mg of pLP-
TRE2-RON and 40mg of pTet-Lac-Hyg for 12h. Cells were first cultured in serum-containing medium for 12h. Then that medium was replaced with
medium containing only MTX (50mgml
 1), MTX and doxycycline (1mgml
 1), and, finally, wortmannin (10nM), MTX, and doxycycline for 60h each. All the
cells were fixed with methanol for 15min and stained with 1% acridine orange for 10min. Cells were examined using fluorescent microscopy (left:  100;
right:  200). Apoptotic cells are indicated by arrows. (B) Levels of apoptotic cells measured using apoptotic body calculation in three different fields were
compared in relation to doxycycline or wortmannin treatment (P¼0.024, t-test).
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of cancer cells
As RT4 cells are resistant to transfection, UB09 cells expressing
a relatively lower level of RON were transfected with plasmid
DNA to express exogenous RON protein. The plasmids (80mg)
pLp-TRE2-RON and pTet-Lac-Hygo at a molar ratio of 1:1 were
transfected into UB09 cells using electroporation (180V, 1000mF).
The cells were subcultured into a six-well tray (1 10
4 per well)
12h later. The cell numbers were counted at a 3-day interval from
day 0 through day 9. Overexpression of RON (UB09/RON) induced
a higher growth rate of UB09 cells compared to the parental cells
(P¼0.0028) (Figure 4).
To evaluate the effect of RON upon cell motility, UB09 cells
(1 10
6) were transfected and cultured on a cover glass for 24h.
Time-lapse recording was then used to evaluate the progression
of wound healing produced by a yellow tip (Ho et al, 2005). The
images were recorded every 20min for a total of 30–48h. It
showed that UB09/RON cells migrated faster than control cells
(P¼0.04) (Figure 5).
To test the effect of RON on apoptosis, UB09 cells were first
treated with MTX for 48h and stained with acridine orange for
apoptotic cell measurement. After MTX treatment (50mgml
 1),
60% of the UB09 cells were apoptotic, but only 25% of the UB09/
RON cells were apoptotic (P¼0.024). The antiapoptotic effect,
however, was blocked by wortmannin treatment (10nM), a P13K
inhibitor (Figure 6). Altogether, overexpression of RON increased
the growth rate and motility of the cells and conferred an
antiapoptotic efficacy on cancer cells through a PI3K-related
signaling pathway.
Immunohistochemical expression of RON or MET receptor
in primary bladder cancer
To clarify the clinical significance of RON receptor expression, we
studied the IHC expression in a transitional-cell bladder-cancer
cohort (n¼183). Membranous staining for RON was seen in only
a few non-neoplastic urothelial cells (Figure 7a). Overexpression
of RON was defined as membranous staining in more than 10%
of tumour cells (Figure 7b). In all, 60 cases (32.8%) were classified
as overexpression of RON, and 14 (23.3%) of those were high
expression (summarised in Table 1). Overexpression of RON was
positively associated with histological grading (P¼0.003), larger
tumours (P¼0.003), nonpapillary contour (P¼0.005), and
tumour stage (P¼0.01) using Fisher’s exact test or the w
2 test
(Table 1).
We also examined the expression of MET in this cohort
(Table 1). In total, 82 cases (44.8%) overexpressed MET, and 27
(32.9%) of those were high expression. MET expression was
positively associated with histological grading, nonpapillary
contour, tumour size, and muscle invasion using Fisher’s exact
test or the w
2 test (all Po0.001). In all study cases, co-expression of
both receptors was detected in 35 cases (19.1%), and expression
of RON or MET was detected in 25 cases (13.7%), and 47 cases
(25.7%), respectively (Table 2).
Prognostic significance of co-expression of RON and MET
in a bladder cancer cohort
In univariate analysis, none of the biological indicators analysed
were correlated with tumour recurrence using the log-rank test
(P40.1, respectively) (data not shown), except that muscle-
invasive tumours tended to have a higher risk of local recurrence
(P¼0.06). Factors associated with decreased patient survival were
overexpression of RON (P¼0.003), co-expression of RON/MET
(P¼0.005), and overexpression of MET (P¼0.02). Patients who
co-expressed RON/MET in their bladder tumours had a signifi-
cantly worse overall survival rate (P¼0.005) or metastasis-free
survival rate (P¼0.01) compared with the remaining expression
status of the two receptors (Figure 8).
Multivariate analysis using a logistic regression model revealed
that neither biological indicator nor expression of RON or MET
or both was associated with tumour recurrence (Table 2). For long-
term survival, important prognostic indicators were multiplicity
(P¼0.009), co-expression of RON/MET (P¼0.03), expression of
RON (P¼0.04), and stage classification (P¼0.05) using the log-
rank test. Overexpression of MET by itself tended to correlate with
poor patient survival in this cohort (P¼0.06). We next used a Cox
proportional hazards models to determine the RR of overall
survival with 95% confidence interval (CI). The RR of poor long-
term survival was 2.46 for multiple tumours, 2.22 for co-expression
of RON and MET, 2.03 for RON expression alone, and 1.98 for
tumour staging.
Significance of co-expression of RON and MET in
superficial bladder cancer
In the subset of superficial bladder cancer (Stages O and A), the
frequency of RON and MET overexpression was 19.4% (18 out of
93) and 32.3% (30 out of 93), respectively (Table 1). Indicators
Figure 7 Immunohistochemical expression of RON protein in the
normal urothelium and bladder cancer cells. (A) Membranous expression
of RON receptor was seen in a few non-neoplastic uroepithelial cells
(highlighted by arrow). (B) The arrows indicate the membranous staining
of RON receptor on cancer cells, representative of a low level of RON
expression (original magnification  300).
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and MET (P¼0.03) and multiplicity (P¼0.05), with RR estimated
at 3.43 (95% CI 1.16–10.12) and 2.22 (95% CI 1.01–4.91),
respectively (data not shown). But expression of RON or MET or
both did not predict the chance of long-term survival for patients
with muscle-invasive tumours.
DISCUSSION
In this study, we found that expression of RON or MET, or both, is
positively associated with aggressive biological indicators and
decreased patient survival, which supports the hypothesis that
RON-related signalling events play an important role in the
progression of bladder cancer. Our results are substantially in
agreement with studies on primary carcinomas of the breast
(Maggiora et al, 1998), colorectum (Zhou et al, 2003), liver (Chen
et al, 1997), and ovary (Maggiora et al, 2003). Moreover, our in
vitro experiments indicated that increased cell growth or motility
and the antiapoptotic effect are the underlying mechanisms for
RON in bladder carcinogenesis. These results are consistent with
reports showing a mitogenic/invasive response induced by
constitutive activation of RON (Santoro et al, 1996) and activation
Table 1 Distribution of RON and MET expression, and biological indicators
RON MET
Clinical characteristics Positive (%) Negative (%) P-value Positive (%) Negative (%) P-value
Histological grade
Grade I 2 (1.1) 20 (10.9) 0.003 4 (2.2) 18 (9.8) o0.0001
Grade II 22 (12.0) 58 (31.7) 25 (13.7) 55 (30.1)
Grade III 36 (19.7) 45 (24.6) 83 (45.4) 28 (15.3)
Tumour shape
Papillary 31 (16.9) 95 (51.9) 0.005 44 (24.0) 82 (44.8) o0.0001
Nonpapillary 29 (15.8) 28 (15.3) 38 (20.8) 19 (10.4)
Tumour size
p1cm 5 (2.7) 31 (16.9) 0.003 8 (4.4) 28 (15.3) 0.0004
41t op3cm 22 (12.0) 54 (29.5) 32 (17.5) 44 (24.0)
43t op5cm 20 (10.9) 22 (12.0) 28 (15.3) 14 (7.7)
45cm 10 (5.5) 7 (3.8) 11 (6.0) 6 (3.3)
N/A
a 3 (1.6) 9 (4.9) 3 (1.6) 9 (4.9)
Multiplicity
Single 28 (15.3) 86 (47.0) 0.37 60 (32.8) 64 (35.0) 0.16
Multiple 22 (12.0) 37 (20.2) 22 (12.0) 37 (20.2)
Stage (TNM staging system)
pTa 9 (4.9) 45 (24.6) 0.01 13 (7.1) 41 (22.4) 0.001
pT1 9 (4.9) 30 (16.4) 17 (9.3) 22 (12.0)
pT2a 16 (8.7) 17 (9.3) 23 (12.6) 10 (5.5)
pT2b 5 (2.7) 7 (3.8) 5 (2.7) 7 (3.8)
pT3 7 (3.8) 5 (2.7) 8 (4.4) 4 (2.2)
pN1/pN2 8 (4.4) 11 (6.0) 13 (7.1) 6 (3.3)
M+ 2 (1.1) 2 (1.1) 2 (1.1) 2 (1.1)
N/A
a 4 (2.2) 6 (3.3) 1 (0.5) 9 (4.9)
CI¼confidence interval. RON¼Recepteur d’Origine Nantais. MET¼c-met protein.
aN/A: not applicable.
Table 2 Prognostic significance of biological indicators and expression of
RON and/or MET for human bladder cancer patients (multivariate Cox
regression analysis)
Recurrence
Survival
Factors P-value P-value RR (95% CI)
Grade 0.60 0.41
Stage 0.14 0.05* 1.98 (1.25–3.14)
Size 0.19 0.35
Shape 0.85 0.60
Multiplicity 0.88 0.009* 2.46 (1.19–3.55)
RON 0.28 0.04* 2.03 (1.08–3.53)
MET 0.40 0.06
RON/MET 0.38 0.03* 2.22 (1.19–3.74)
CI¼confidence interval. RON¼Recepteur d’Origine Nantais. MET¼c-met protein.
*Pp0.05.
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Figure 8 Prognostic significance of RON and/or MET expression in
bladder cancer patients. Patients who co-expressed RON and MET had a
significantly worse metastasis-free survival compared with patients who had
single-receptor-positive tumours or no receptor expression (P¼0.01).
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sof signalling pathways, including PI3K, in regulating cell adhesion,
motility, growth, and survival after stimulation with MSP
(Danilkovitch et al, 2000; Peace et al, 2001).
The most intriguing observation of this investigation, however,
is the prognostic importance of the co-expression of RON and
MET, especially for patients with superficial bladder cancer
(P¼0.03; RR¼3.43). This observation has clinical implications
because this group of patients represents the largest group of
urological malignancy in common practice. Co-expression of both
receptors thus appears to signify a distinctive ‘invasive growth’
programme for carcinoma cells. This conclusion essentially
concurs with the current hypothesis of crosstalk between
subfamily members of the ErbB receptors and their prognostic
significance (Wada et al, 1990; Sliwkowski et al, 1994; Pinkas-
Kramarski et al, 1996; Chow et al, 2001). Therefore, evaluation of
the RON and MET expression status may identify a subset of
bladder cancer patients who might require more intensive
treatment.
Further support for clinical relevance of RON/MET interaction
in human cancer comes from in vitro experiments by Follenzi et al
(2000). First, MET and RON exist on the cell membrane surface
as preformed dimers before ligand stimulation, and there is a bi-
directional transphosphorylation between MET and RON after
stimulation with either hepatocyte growth factor or MSP. Second,
although RON is a less efficient kinase than MET, formation of
MET/RON complexes induces a more efficient RON transpho-
sphorylation by MET, leading to a more sustained signal than that
induced by the RON/RON homodimer. Activation of both MET
and RON may thus possibly initiate a cooperative or synergistic
response to their ligands. Further investigation is mandatory to
clarify the benefits of combined therapies against RON/MET
receptors and their signal transducers.
In our series, the most important prognostic indicators for
bladder cancer patients were, first, multiple tumours at diagnosis
and, second, advanced tumour stage. A similar discovery was also
reported in some earlier studies (Holmang et al, 1995; Crew et al,
1997; Cheng et al, 2002), although no complete rationale was
proposed to explain for the occurrence. Since dysplastic change in
the field mucosa correlates well with clinical outcome in cancer
patients, multiple tumours at diagnosis may represent a sign of
unstable urothelium. Alternatively, if multiple bladder cancers are
monoclonal in origin (Sidransky et al, 1992), the occurrence might
signify an intraluminal spreading and implantation of tumour
cells. A prospective study is necessary to verify the consequences
of such spreading and implantation before determining what
might be appropriate treatment plans for bladder cancer patients.
In summary, the results of our study indicate that RON-related
molecular events are important in the progression of bladder
carcinogenesis. Evaluation of the expression pattern of MET and
RON is of great help in selecting bladder cancer patients for more
aggressive therapy.
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